Neural tube defects

Obstetrics and Gynecology

Volumn 102, Issue 1, 2003, Pages 203-213

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; AMINOPTERIN; CARBAMAZEPINE; FOLIC ACID; PHENYTOIN; VALPROIC ACID;

ANENCEPHALUS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DELIVERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISABILITY; DISEASE MARKER; DISEASE PREDISPOSITION; DRUG EFFECT; DRUG EFFICACY; EMBRYOLOGY; EPIDEMIOLOGICAL DATA; FETUS SURGERY; GENETIC DISORDER; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; MATERNAL SERUM; NEURAL TUBE DEFECT; PATHOPHYSIOLOGY; PRENATAL DIAGNOSIS; PRENATAL SCREENING; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SPINA BIFIDA; SUPPLEMENTATION; SURVIVAL; TREATMENT OUTCOME; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

EID: 0038384006     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(03)00610-0     Document Type: Short Survey

References (81)

1. Cragan JD, Roberts HE, Edmonds LD, Khoury MJ, Kirby RS, Shaw GM, et al. Surveillance for anencephaly and spina bifida and the impact of prenatal diagnosis - United States, 1985-1994. MMWR CDC Surveill Summ 1995; 44(4):1-13. (Level III)
2. Botto LD, Moore CA, Khoury MJ, Erickson JD. Neural-tube defects. N Engl J Med 1999;341:1509-19. (Level III)
3. Bowman RM, McLone DG, Grant JA, Tomita T, Ito JA. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg 2001;34:114-20. (Level III)
4. Van Allen MI, Kalousek DK, Chernoff GF, Juriloff D, Harris M, McGillivray BC, et al. Evidence for multi-site closure of the neural tube in humans. Am J Med Genet 1993;47:723-43. (Level III)
5. Seller MJ. Sex, neural tube defects, and multisite closure of the human neural tube. Am J Med Genet 1995;58:332-6. (Level II-2)
6. Steinbok P, Irvine B, Cochrane DD, Irwin BJ. Long-term outcome and complications of children born with meningomyelocele. Childs Nerv Syst 1992;8:92-6. (Level II-2)
7. Hunt GM. The Casey Holter lecture. Non-selective intervention in newborn babies with open spina bifida: the outcome 30 years on for the complete cohort. Eur J Pediatr Surg 1999;9(suppl 1):5-8. (Level II-2)
8. Storrs BB. Ventricular size and intelligence in myelodys-plastic children. In: Martin AE, editor. Concepts in pediatric neurosurgery. Vol 8. Basel: Karger; 1988. p. 51-6. (Level II-3)
9. Rolle U, Grafe G. About the rate of shunt complications in patients with hydrocephalus and myelomeningocele. Eur J Pediatr Surg 1999;9(suppl 1):51-2. (Level III)
10. Nelson MD Jr, Bracchi M, Naidich TP, McLone DG. The natural history of repaired myelomeningocele. Radiographics 1988;8:695-706. (Level III)
11. Selber P, Dias L. Sacral-level myelomeningocele: long-term outcome in adults. J Pediatr Orthop 1998;18:423-7. (Level II-3)
12. McDonnell GV McCann JP. Why do adults with spina bifida and hydrocephalus die? A clinic-based study. Eur J Pediatr Surg 2000;10(suppl 1):31-2. (Level III)
13. Joyner BD, McLorie GA, Khoury AE. Sexuality and reproductive issues in children with myelomeningocele. Eur J Pediatr Surg 1998;8:29-34. (Level III)
14. Caldarelli M, Di Rocco C, Colosimo C Jr, Fariello G, Di Gennaro M. Surgical treatment of late neurological deterioration in children with myelodysplasia. Acta Neurochir (Wien) 1995;137:199-206. (Level III)
15. McLone DG, Czyzewski D, Raimondi AJ, Sommers RC. Central nervous system infections as a limiting factor in the intelligence of children with myelomeningocele. Pediatrics 1982;70:338-42. (Level III)
16. Hall JG, Friedman JM, Kenna BA, Popkin J, Jawanda M, Arnold W. Clinical, genetic, and epidemiological factors in neural tube defects. Am J Hum Genet 1988;43:827-37. (Level II-3)
17. Nussbaum RL, McInnes RR, Willard HF. Genetics of disorders with complex inheritance. In: Thompson & Thompson genetics in medicine. 6th ed. Philadelphia (PA): W.B. Saunders; 2001. p. 289-310. (Level III)
18. Aitken DA, Crossley JA, Spencer K. Prenatal screening for neural tube defects and aneuploidy. In: Rimoin DL, Connor JM, Pyeritz RE, Korf BR, editors. Emery and Rimoin's principles and practice of medical genetics 4th ed. New York: Churchill & Livingstone; 2002. p. 763-801. (Level III)
19. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural-tube defects in 34 infants prentally exposed to antiepileptic drugs. Neurology 1992;42(4 suppl 5):111-8. (Level III)
20. Shaw GM, Todoroff K, Velie EM, Lammer EJ. Maternal illness, including fever and medication use as risk factors for neural tube defects. Teratology 1998;57:1-7. (Level II-2)
21. van der Put NM, van Straaten HW, Trijbels FJ, Blom HJ. Folate, homocysteine and neural tube defects: an overview. Exp Biol Med (Maywood) 2001;226:243-70. (Level III)
22. Lammer EJ, Sever LE, Oakley GP Jr. Teratogen update: valproic acid. Teratology 1987;35:465-73. (Level III)
23. Reece EA, Hobbins JC. Diabetic embryopathy: pathogenesis, prenatal diagnosis and prevention. Obstet Gynecol Surv 1986;41:325-35. (Level III)
24. Feuchtbaum LB, Currier RJ, Riggle S, Roberson M, Lorey FW, Cunningham GC. Neural tube defect prevalence in California (1990-1994): eliciting patterns by type of defect and maternal race/ethnicity. Genet Test 1999;3:265-72. (Level II-3)
25. Jones KL, editor. Smith's recognizable patterns of human malformation. 5th ed. Philadelphia (PA): W B Saunders; 1997. (Level III)
26. Hibbard ED, Smithells RW. Folic acid metabolism and human embryopathy. Lancet 1965;1:1254. (Level III)
27. Smithells RW, Nevin NC, Seller MJ, Sheppard S, Harris R, Read AP, et al. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet 1983;1:1027-31. (Level II-2)
28. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br Med J (Clin Res Ed) 1981;282:1509-11. (Level I)
29. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. JAMA 1988;260:3141-5. (Level II-2)
30. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991;338:131-7. (Level I)
31. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992;327:1832-5. (Level I)
32. Berry RJ, Li Z, Erickson JD, Li S, Moore CA, Wang H, et al. Prevention of neural-tube defects with folic acid in China. China-U.S. Collaborative Project for Neural Tube Defect Prevention [corrected; erratum N Engl J Med 1999;341:24 and N Engl J Med 2000;342:7]. N Engl J Med 1999;341:1485-90. (Level II-2)
33. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software. (Level I)
34. van der Put MN, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070-1. (Level II-2)
35. van der Put MN, Eskes TK, Blom HJ. Is the common 677 C→T mutation in the methylenetetrahydrofolate reductase gene a risk factor for neural tube defects? A meta-analysis. QJM 1997;90:111-5. (Meta-analysis)
36. van der Put MN, Blom HJ. Neural tube defects and a disturbed folate dependent homocysteine metabolism. Eur J Obstet Gynecol Reprod Biol 2000;92:57-61. (Level III)
37. Use of folic acid for prevention of spina bifida and other neural tube defects - 1983-1991. MMWR Morb Mortal Wkly Rep 1991;40:513-6. (Level III)
38. Knowledge and use of folic acid by women of childbearing age - United States, 1995 and 1998. MMWR Morb Mortal Wkly Rep 1999;48:325-7. (Level III)
39. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid - FDA. Final rule. Fed Regist 1996;61:8781-97. (Level III)
40. Rader J, Weaver CM, Angyal G. Advances in the analysis of folates in foods. Food Test Anal 1999;5:14-32. (Level III)
41. Wald NJ, Law MR, Morris JK, Wald DS. Quantifying the effect of folic acid. Lancet 2001;358:2069-73. (Level III)
42. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD, Wong LY. Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 2001;285:2981-6. (Level II-2)
43. Lindenbaum J, Healton EB, Savage DG, Brust JC, Garrett TJ, Podell ER, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720-8. (Level II-3)
44. Wald NJ, Bower C. Folic acid, pernicious anemia, and prevention of neural tube defects. Lancet 1994;343:307. (Level III)
45. Biale Y Lewenthal H. Effect of folic acid supplementation on congenital malformations due to anticonvulsive drugs. Eur J Obstet Gynecol Reprod Biol 1984;18:211-6. (Level II-2)
46. Rothman KJ, Moore LL, Singer MR, Nguyen US, Mannino S, Milunsky A. Teratogenicity of high vitamin A intake. N Engl J Med 1995;333:1369-73. (Level III)
47. Milunsky A. Maternal serum screening for neural tube and other defects. In: Genetic disorders and the fetus: diagnosis, prevention, and treatment. 4th ed. Baltimore (MD): Johns Hopkins University Press; 1998. p. 635-701. (Level III)
48. Wald NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FR. Maternal serum-alpha-fetoprotein measurement in antenatal screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. Lancet 1977;1:1323-32. (Level II-2)
49. Haddow JE, Kloza EM, Smith DE, Knight GJ. Data from an alpha-fetoprotein pilot screening program in Maine. Obstet Gynecol 1983;62:556-60. (Level III)
50. Burton BK, Sowers SG, Nelson LH. Maternal serum alpha-fetoprotein screening in North Carolina: experience with more than twelve thousand pregnancies. Am J Obstet Gynecol 1983;146:439-44. (Level III)
51. Milunsky A. Prenatal detection of neural tube defects. VI. Experience with 20,000 pregnancies. JAMA 1980;244:2731-5. (Level II-2)
52. Loft AG, Hogdall E, Larsen SO, Norgaard-Pedersen B. A comparison of amniotic fluid alpha-fetoprotein and acetylcholinesterase in the prenatal diagnosis of open neural tube defects and anterior abdominal wall defects. Prenat Diagn 1993;13:93-109. (Level II-2)
53. James SJ, Pogribna M, Pogribny IP, Melnyk S, Hine RJ, Gibson JB, et al. Abnormal folate metabolism and mutation in the methylenetetrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am J Clin Nutr 1999;70:495-501. (Level II-2)
54. Watson WJ, Chescheir NC, Katz VL, Seeds JW. The role of ultrasound in evaluation of patients with elevated maternal serum alpha-fetoprotein: a review. Obstet Gynecol 1991;78:123-8. (Level III)
55. Harmon JP, Hiett AK, Palmer CG, Golichowski AM. Prenatal ultrasound detection of isolated neural tube defects: is cytogenetic evaluation warranted? Obstet Gynecol 1995;86:595-9. (Level II-3)
56. Gardner RJ, Sutherland GR. Prenatal diagnostic procedures. In: Chromosome abnormalities and genetic counseling. Oxford monographs on medical genetics no. 29. 2nd ed. New York: Oxford University Press; 1996. p. 336-44. (Level III)
57. Lennon CA, Gray DL. Sensitivity and specificity of ultrasound for the detection of neural tube and ventral wall defects in a high-risk population. Obstet Gynecol 1999; 94:562-6. (Level II-2)
58. Crane JP, LeFevre ML, Winborn RC, Evans JK, Ewigman BG, Bain RP, et al. A randomized trial of prenatal ultra-sonographic screening: impact on the detection, management, and outcome of anomalous fetuses. The RADIUS Study Group. Am J Obstet Gynecol 1994;171:392-9. (Level I)
59. Nadel AS, Green JK, Holmes LB, Frigoletto FD Jr, Benacerraf BR. Absence of need for amniocentesis in patients with elevated levels of maternal serum alpha-fetoprotein and normal ultrasonographic examinations. N Engl J Med 1990;323:557-61. (Level II-3)
60. Reichler A, Hume RF Jr, Drugan A, Bardicef M, Isada NB, Johnson MP, et al. Risk of anomalies as a function of level of elevated maternal serum alpha-fetoprotein. Am J Obstet Gynecol 1994;171:1052-5. (Level III)
61. Platt LD, Feuchtbaum L, Filly R, Lustig L, Simon M, Cunningham GC. The California Maternal Serum Alpha-Fetoprotein Screening Program: the role of ultrasonography in the detection of spina bifida. Am J Obstet Gynecol 1992;166:1328-9. (Level II-2)
62. Hogge WA, Thiagarajah S, Ferguson JE 2nd, Schnatterly PT, Harbert GM Jr. The role of ultrasonography and amniocentesis in the evaluation of pregnancies at risk for neural tube defects. Am J Obstet Gynecol 1989;161:520-3; discussion 523-4. (Level II-2)
63. Drugan A, Zador IE, Syner FN, Sokol RJ, Sacks AJ, Evans MI. A normal ultrasound does not obviate the need for amniocentesis in patients with elevated serum alpha-fetoprotein. Obstet Gynecol 1988;72:627-30. (Level II-2)
64. Vindla S, Sahota DS, Coppens M, James DK. Computerized analysis of behavior in fetuses with congenital abnormalities. Ultrasound Obstet Gynecol 1997;9:302-9. (Level II-3)
65. Wilkins-Haug L. Considerations for delivery of infants with congenital abnormalities. Obstet Gynecol Clin North Am 1999;26:399-412. (Level III)
66. Cochrane D, Aronyk K, Sawatzky B, Wilson D, Steinbok P. The effects of labor and delivery on spinal cord function and ambulation in patients with meningomyelocele. Childs Nerv Syst 1991;7:312-5. (Level II-2)
67. Bensen JT, Dillard RG, Burton BK. Open spina bifida: does cesarean section delivery improve prognosis? Obstet Gynecol 1988;71:532-4. (Level II-3)
68. Sakala EP, Andree I. Optimal route of delivery for meningomyelocele. Obstet Gynecol Surv 1990;45:209-12. (Level II-3)
69. Hill AE, Beattie F. Does caesarean section delivery improve neurological outcome in open spina bifida? Eur J Pediatr Surg 1994;4(suppl 1):32-4. (Level III)
70. Merrill DC, Goodwin P, Burson JM, Sato Y Williamson R, Weiner CP. The optimal route of delivery for fetal meningomyelocele. Am J Obstet Gynecol 1998;179:235-40. (Level II-3)
71. Luthy DA, Wardinsky T, Shurtleff DB, Hollenbach KA, Hickok DE, Nyberg DA, et al. Cesarean section before the onset of labor and subsequent motor function in infants with meningomyelocele diagnosed antenatally. N Engl J Med 1991;324:662-6. (Level II-3)
72. Meuli M, Meuli-Simmen C, Hutchins GM, Seller MJ, Harrison MR, Adzick NS. The spinal cord lesion in human fetuses with myelomeningocele: implications for fetal surgery. J Pediatr Surg 1997;32:448-52. (Level III)
73. Holzbeierlein J, Pope JC IV Adams MC, Bruner J, Tulipan N, Brock JW 3rd. The urodynamic profile of myelodysplasia in childhood with spinal closure during gestation. J Urol 2000;164:1336-9. (Level III)
74. Hirose S, Farmer DL, Albanese CT. Fetal surgery for myelomeningocele. Curr Opin Obstet Gynecol 2001;13:215-22. (Level III)
75. Tulipan N, Hernanz-Schulman M, Lowe LH, Bruner JP. Intrauterine myelomeningocele repair reverses preexisting hindbrain herniation. Pediatr Neurosurg 1999;31:137-42. (Level III)
76. Sutton LN, Adzick NS, Bilaniuk LT, Johnson MP, Crombelholme TM, Flake AW. Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningo-cele. JAMA 1999;282:1826-31. (Level III)
77. Ranzini AC, White M, Guzman ER, Scorza WE. Prenatal sonographic diagnosis of uterine rupture following open fetal surgery. Obstet Gynecol 1999;93:826-7. (Level III)
78. Bruner JP, Tulipan N, Paschall RL, Boehm FH, Walsh WF, Silva SR, et al. Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus. JAMA 1999;282:1819-25. (Level II-2)
79. Bealer JF, Raisanen J, Skarsgard ED, Long SR, Wong K, Filly RA, et al. The incidence and spectrum of neurological injury after open fetal surgery. J Pediatr Surg 1995;30:1150-4. (Level III)
80. Farrell JA, Albanese CT, Jennings RW, Kilpatrick SJ, Bratton BJ, Harrison MR. Maternal fertility is not affected by fetal surgery. Fetal Diagn and Ther 1999;14:190-2. (Level III)
81. Mazzola CA, Albright AL, Sutton LN, Tuite GF, Hamilton RL, Pollack IF. Dermoid inclusion cysts and early spinal cord tethering after fetal surgery for myelomeningocele. N Engl J Med 2002;347:256-9. (Level III)